ErepoXen: Phase III started

Xenetic said partner SynBio began a 24-month, open-label, Russian Phase III trial comparing ErepoXen vs. Aranesp darbepoetin alfa in 150 patients with stage 3 or 4 CKD. Amgen Inc. (NASDAQ:AMGN, Thou...